Abstract
To investigate the expression profiles of microRNA-96 (miR-96) in cervical squamous cell carcinoma before and after neoadjuvant chemotherapy and to explore the effects of the treatment on expression of miR-96 and its relationship with clinical efficacy, chemosensitivity, and clinicopathologic features. The expression of miR-96 was detected by real-time polymerase chain reaction in 28 patients with cervical squamous cell carcinoma (stage 1b2-2a) before and after neoadjuvant chemotherapy. The correlations between the change of miR-96 and related clinicopathologic features of cervical cancer (age, pathologic pattern, histological grade, depths of interstitial infiltration, lymph node metastasis, and clinical stage) were further analyzed. The relative expression of miR-96 in cervical squamous cell carcinoma before treatment was (5.330 ± 5.069) times higher than after the treatment with neoadjuvant chemotherapy (P=0.000).The relative change of the expressions of miR-96 in cervical cancer patients between pre-and post-neoadjuvant chemotherapy was closely related with clinicopathological features:it was significantly smaller in poorly-or moderately-differentiated patients (2.345 ± 1.153) than in well-differentiated patients (9.941 ± 5.359) (P=0.000), significantly larger in patients with the tumor invasion depth < 1/2 interstice (8.236 ± 5.399) than in ≥1/2 interstice (1.978 ± 1.030) (P=0.000), and significantly smaller in patients with lymph node metastasis (1.848 ± 0.959) than those without lymph node metastasis (7.942 ± 5.348) (P=0.000). There was no significant difference in terms of age and clinical stages (1b2-2a) (P>0.05). Neoadjuvant chemotherapy can effectively reduce miR-96 expression in cervical squamous cell carcinoma tissues.It is therefore speculated that detection of the miR-96 expression before the chemotherapy for cervical cancer may be helpful to predict the therapeutic efficacy and sensitivity of the treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have